Vacuna del papilomavirus en el Perú

Gino Venegas Rodríguez; Alcedo Jorges Nimer; Oscar Galdos Kajatt

doi:10.31403/rpgo.v66i2286

Authors

Gino Venegas Rodríguez Ginecologist Oncologist; Faculty of Human Medicine, Universidad de Piura, Lima, Peru; Clinica Angloamericana, Lima, Peru https://orcid.org/0000-0002-4114-0291
Alcedo Jorges Nimer Ministry of Health, Peru https://orcid.org/0000-0002-4680-1140
Oscar Galdos Kajatt Faculty of Human Medicine, Universidad de Piura, Lima, Peru; Demujer, Women’s Oncology Center, Lima, Peru https://orcid.org/0000-0002-1489-3829

DOI:

https://doi.org/10.31403/rpgo.v66i2286

Keywords:

Human papillomavirus, Vaccination, Human papillomavirus recombinant vaccine, Papillomaviridae, Peru

Abstract

Cervical cancer is a public health concern. The human papillomavirus (HPV) vaccine protects against infection with HPV. The vaccine has been shown to be effective in preventing premalignant lesions and cervical cancer, as well as lesions of the vulva, vagina, anal canal, penis, and oropharynx. It has also proven to be cost effective and supports the idea of introducing a national vaccination strategy. The HPV vaccine could be the ideal tool for health systems where secondary prevention has not been successful over time. The implementation of the vaccination program in Peru began in 2011. Currently, in Peru, the indication for vaccination is with the quadrivalent vaccines for 5th grade girls from public and private schools. It is administered in 2 doses, 0-6 months. In 2019, coverage in Peru was 87% (234 535 girls) for the first dose and 78% (211 339 girls) for the second dose.